Vaccination against pneumococcal infection in anamnesis;
Application of preparations of immune globulin or blood transfusion within last three months prior to clinical studies;
Prolonged use (more than 14 days) immunosuppressants or other immunosuppressive drugs within 6 months prior to the start of the study;
Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection;
A history or currently hematologic and other cancers;
A positive reaction for HIV infection, viral hepatitis B and hepatitis C;
The presence of respiratory, cardio-vascular insufficiency, impaired liver and kidney function, established during a physical examination at visit number 1;
Pronounced congenital defects or serious chronic diseases in the acute stage, including any clinically important exacerbation of chronic diseases of the liver, kidney, cardiovascular, nervous system, mental diseases or metabolic disorders, confirmed by the history or objective examination (pulmonary: cystic fibrosis, lung abscess, empyema, active tuberculosis; extra-pulmonary: congestive heart failure, malabsorption, chronic renal and hepatic failure, cirrhosis, malignancy, immunodeficiency, cirrhosis of the liver);
Severe allergic reactions in anamnesis of autoimmune disease;
The presence of acute infectious and/or communicable illnesses within 1 month prior to study;
History of chronic alcohol abuse and/or drug use;
Exacerbation of chronic diseases;
Breastfeeding;
Pregnancy;
Participation in any other clinical study within the last 3 months.

NCT02787863_exc_T1
Condition
pneumococcal infection
NCT02787863_exc_T2
Procedure
Vaccination
NCT02787863_exc_T3
Drug
preparations of immune globulin
NCT02787863_exc_T4
Procedure
blood transfusion
NCT02787863_exc_T5
Temporal
within last three months prior to clinical studies
NCT02787863_exc_T6
Scope
preparations of immune globulin or blood transfusion
NCT02787863_exc_T7
Temporal
more than 14 days
NCT02787863_exc_T8
Temporal
Prolonged use
NCT02787863_exc_T9
Drug
immunosuppressants
NCT02787863_exc_T10
Qualifier
other
NCT02787863_exc_T11
Drug
immunosuppressive drugs
NCT02787863_exc_T12
Temporal
within 6 months prior to the start of the study
NCT02787863_exc_T13
Scope
immunosuppressants or other immunosuppressive drugs
NCT02787863_exc_T14
Condition
unosuppressive or dition, i
NCT02787863_exc_T15
Condition
immunodeficient condition
NCT02787863_exc_T16
Condition
HIV infection
NCT02787863_exc_T17
Scope
immunosuppressive or immunodeficient condition
NCT02787863_exc_T19
Measurement
reaction for HIV infection
NCT02787863_exc_T20
Value
positive
NCT02787863_exc_T21
Measurement
ion for HIV  hepatitis B an
NCT02787863_exc_T22
Measurement
ion for HIV itis C;
The
NCT02787863_exc_T23
Scope
reaction for HIV infection, viral hepatitis B and hepatitis C
NCT02787863_exc_T24
Condition
cardio-vascular insufficiency
NCT02787863_exc_T25
Condition
atory, card iciency, impa
NCT02787863_exc_T26
Condition
impaired liver
NCT02787863_exc_T27
Condition
ed liver  function, est
NCT02787863_exc_T28
Temporal
at visit number 1
NCT02787863_exc_T29
Scope
respiratory, cardio-vascular insufficiency, impaired liver and kidney function
NCT02787863_exc_T30
Condition
congenital defects
NCT02787863_exc_T31
Condition
chronic diseases
NCT02787863_exc_T32
Qualifier
acute stage
NCT02787863_exc_T33
Qualifier
clinically important
NCT02787863_exc_T34
Qualifier
serious
NCT02787863_exc_T35
Condition
exacerbation
NCT02787863_exc_T36
Condition
diseases of the liver
NCT02787863_exc_T37
Qualifier
chronic
NCT02787863_exc_T38
Condition
s of the liver,  card
NCT02787863_exc_T39
Condition
s of the liver, ascular, nervo  ment
NCT02787863_exc_T40
Condition
s of the liver,  system, ment
NCT02787863_exc_T41
Condition
mental diseases
NCT02787863_exc_T42
Condition
metabolic disorders
NCT02787863_exc_T43
Condition
cystic fibrosis
NCT02787863_exc_T44
Condition
lung abscess
NCT02787863_exc_T45
Condition
empyema
NCT02787863_exc_T46
Qualifier
active
NCT02787863_exc_T47
Condition
tuberculosis
NCT02787863_exc_T48
Condition
congestive heart failure
NCT02787863_exc_T49
Condition
malabsorption
NCT02787863_exc_T50
Condition
hepatic failure
NCT02787863_exc_T51
Condition
nd he , cirrh
NCT02787863_exc_T52
Qualifier
chronic
NCT02787863_exc_T53
Scope
renal and hepatic failure
NCT02787863_exc_T54
Condition
cirrhosis
NCT02787863_exc_T55
Condition
malignancy
NCT02787863_exc_T56
Condition
immunodeficiency
NCT02787863_exc_T57
Condition
cirrhosis of the liver
NCT02787863_exc_T58
Scope
pulmonary: cystic fibrosis, lung abscess, empyema, active tuberculosis; extra-pulmonary: congestive heart failure, malabsorption, chronic renal and hepatic failure, cirrhosis, malignancy, immunodeficiency, cirrhosis of the liver
NCT02787863_exc_T59
Scope
diseases of the liver, kidney, cardiovascular, nervous system
NCT02787863_exc_T60
Scope
exacerbation of chronic diseases of the liver, kidney, cardiovascular, nervous system, mental diseases or metabolic disorders
NCT02787863_exc_T61
Scope
congenital defects or serious chronic diseases in the acute stage
NCT02787863_exc_T62
Qualifier
Severe
NCT02787863_exc_T63
Condition
allergic reactions
NCT02787863_exc_T64
Qualifier
acute
NCT02787863_exc_T65
Condition
s and/or c  within 
NCT02787863_exc_T66
Condition
communicable illnesses
NCT02787863_exc_T67
Temporal
within 1 month prior to study
NCT02787863_exc_T68
Scope
infectious and/or communicable illnesses
NCT02787863_exc_T69
Condition
alcohol abuse
NCT02787863_exc_T70
Condition
drug use
NCT02787863_exc_T71
Qualifier
chronic
NCT02787863_exc_T72
Scope
alcohol abuse and/or drug use
NCT02787863_exc_T73
Condition
Exacerbation
NCT02787863_exc_T74
Condition
chronic diseases
NCT02787863_exc_T75
Observation
Breastfeeding
NCT02787863_exc_T76
Condition
Pregnancy
NCT02787863_exc_T77
Observation
in any other cli  within the l
NCT02787863_exc_T78
Qualifier
any other
NCT02787863_exc_T79
Temporal
within the last 3 months
NCT02787863_exc_T80
Reference_point
study